## **Quarterly Industry Update**

As of September 30, 2014 Industry: Medical Device




## **Industry Summary**

Cogent Valuation identified publicly traded companies, IPOs, and recent M&A transactions within the Medical Device industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Since September 30, 2013, the median 52-week share price return of the Medical Device industry has increased by 17.1%. In the last quarter, the median price-to-earnings multiple decreased from 21.8x to 21.2x.

Comparable Public Company Key Statist	rics										
Median 52-Week Return	17.1%	Median EV/Revenue Multiple		3.4x	Median Price/Earnings Multiple			21.2x			
Median 3-Year CAGR Return	18.1%	Median EV/EBITDA Multiple		12.2x	Median EV/Gross CF Multiple			17.6x			
Comparable Public Company Market Price Returns (As of September 30, 2014)											
	YTD	3 Month	1 Year	2 Year	3 Year	5 Year	2013	2012	2011	2010	2009
Medtronic plc	7.9%	-2.8%	16.3%	19.9%	23.1%	11.0%	39.9%	7.2%	3.1%	-15.7%	40.0%
Boston Scientific Corporation	-1.7%	-7.5%	0.6%	43.4%	26.0%	2.2%	109.8%	7.3%	-29.5%	-15.9%	16.3%
St. Jude Medical Inc.	-2.9%	-13.2%	12.1%	19.5%	18.4%	9.0%	71.4%	5.4%	-19.8%	16.2%	11.6%
CR Bard Inc.	6.5%	-0.2%	23.9%	16.8%	17.7%	12.7%	37.0%	14.3%	-6.8%	17.8%	-7.5%
Edwards Lifesciences Corp.	55.3%	19.0%	46.7%	-2.5%	12.7%	23.9%	-27.1%	27.5%	-12.5%	86.2%	58.1%
CONMED Corporation	-13.3%	-16.6%	8.5%	13.7%	17.0%	14.0%	52.1%	8.9%	-2.9%	15.9%	-4.8%
Greatbatch, Inc.	-3.7%	-13.1%	25.2%	32.3%	28.7%	13.7%	90.4%	5.2%	-8.5%	25.6%	-27.3%
Thoratec Corp.	-27.0%	-23.3%	-28.3%	-12.1%	-6.4%	-2.5%	-2.5%	11.8%	18.5%	5.2%	-17.1%
CryoLife Inc.	-11.0%	10.3%	41.0%	21.2%	30.0%	4.4%	78.0%	29.8%	-11.4%	-15.6%	-33.9%
ABIOMED, Inc.	-7.1%	-1.2%	30.3%	8.8%	31.1%	20.7%	99.0%	-27.2%	92.2%	10.1%	-46.8%
Cardiovascular Systems Inc.	-31.1%	-24.2%	17.9%	43.0%	27.5%	26.6%	173.2%	27.4%	-15.5%	154.0%	N/A
Heartware International Inc.	-17.3%	-12.3%	6.1%	-9.4%	6.4%	21.0%	11.9%	21.7%	-21.2%	146.9%	N/A
AtriCure, Inc.	-21.2%	-19.9%	34.1%	40.7%	14.8%	25.5%	170.7%	-37.8%	8.1%	70.0%	172.1%
Stereotaxis Inc.	-35.9%	-34.6%	-30.3%	27.4%	-40.7%	-44.6%	42.0%	-69.0%	-78.5%	-2.5%	-10.7%
Median of Industry Public Companies	-9.1%	-12.7%	17.1%	19.7%	18.1%	13.2%	61.7%	8.1%	-10.0%	16.1%	-6.2%

(Multiple year periods are calculated as the average annual return.)



Median Gross Profit, EBITDA, Net Income and Gross Cash Flow Margins
80.0% —
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
5ep 2012 Dec 2013 Hat 2013 Inv 2013 Seb 5013 Dec 5013 Hat 2014 Inv 2014 Seb 5014
Gross Profit — EBITDA — — Net Income — · · - Gross Cash Flow

Median Public Company Multiples of the Medical Device Industry									
Date:	9/30/2012	12/31/2012	3/31/2013	6/30/2013	9/30/2013	12/31/2013	3/31/2014	6/30/2014	9/30/2014
EV/Revenues Multiple	2.6x	2.5x	2.7x	3.0x	3.2x	3.5x	3.6x	3.5x	3.4x
EV/EBITDA Multiple	9.6x	8.9x	9.2x	9.3x	10.3x	12.1x	12.8x	12.6x	12.2x
Price/Earnings Multiple	23.8x	20.6x	20.6x	22.0x	23.6x	21.9x	25.6x	21.8x	21.2x
EV/Gross Cash Flows Multiple	18.2x	15.8x	19.2x	19.5x	20.5x	21.3x	21.6x	20.0x	17.6x

This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report.

## **Quarterly Industry Update**


As of September 30, 2014 Industry: Medical Device



Industry Initial Public Offerings (dollars in millions, except share prices)										
Offer Date	Company Name	Offer Price	Shares Offered	Amount Raised	Total Assets	<u>Debt</u>	LTM Revenues	LTM EBITDA	LTM Net Income	LTM Cash Flows
11/17/2011	Sphere Medical Holding PLC	\$1.46	15.1	\$22.1	\$19.4	\$0.0	\$0.0	(\$7.0)	(\$8.1)	(\$6.7)
4/18/2011	InspireMD, Inc.	\$1.50	7.0	\$10.4	\$12.7	\$1.5	\$4.5	(\$3.3)	(\$4.6)	(\$3.2)
10/22/2010	STENTYS Société anonyme	\$16.70	1.9	\$31.6	\$34.7	\$1.7	\$0.3	(\$9.4)	(\$9.8)	(\$9.1)
7/7/2010	Carmat Société Anonyme	\$23.67	0.8	\$19.6	\$8.7	\$0.0	\$4.4	\$0.0	(\$4.3)	\$0.3
2/10/2011	Kips Bay Medical, Inc.	\$8.00	2.1	\$16.5	\$6.2	\$0.0	\$0.2	(\$8.6)	(\$10.9)	(\$8.6)
12/12/2005	Lombard Medical Technologies Limited	\$2.82	14.4	\$47.0	\$11.8	\$7.4	\$0.1	(\$9.0)	(\$13.0)	(\$8.6)
8/5/2005	AtriCure, Inc.	\$12.00	4.0	\$48.0	\$12.5	\$0.0	\$25.5	(\$5.8)	(\$10.9)	(\$4.7)
1/27/2005	Heartware International Inc.	\$0.39	60.0	\$23.3	N/A	N/A	N/A	N/A	N/A	N/A
8/11/2004	Stereotaxis Inc.	\$8.00	5.0	\$44.0	\$41.1	\$6.0	\$9.9	(\$29.8)	(\$30.5)	(\$29.2)
Median of All IPOs		nm	nm	\$23.3	\$12.6	\$0.7	\$2.3	(\$7.8)	(\$10.3)	(\$7.6)

nm: not meaningful

Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)									
Transaction Date	Target	Associates	Transaction Size	% Bought					
		<u>Acquirer</u>							
8/8/2014	Avalon Laboratories, LLC	Nordson Medical	\$180.0	100%					
7/1/2014	ECP Entwick.	ABIOMED Europe GmbH	\$34.3	100%					
1/8/2014	Grikin Advanced Materials	GRINM Semiconductor	\$33.9	96%					
12/31/2013	Endoscopic Technologies, Inc.	AtriCure, Inc.	\$60.7	100%					
6/30/2013	Terumo Heart, Inc.	Thoratec Corp.	\$56.5	100%					
12/19/2012	Thomas Medical Products	Merit Medical Systems, Inc.	\$167.0	100%					
11/30/2012	Defibtech, LLC	Resuscitation Solution, Inc.	\$49.0	100%					
11/19/2012	Vessix Vascular, Inc.	Boston Scientific Corporation	\$425.0	100%					
10/29/2012	Neovasc Medical Ltd., XenoSure	LeMaitre Vascular, Inc.	\$4.6	100%					
10/9/2012	Rhythmia Medical, Inc.	Boston Scientific Corporation	\$265.0	100%					
10/4/2012	BridgePoint Medical, Inc.	Boston Scientific Corporation	\$110.0	100%					
8/16/2012	St. Jude Medical, Inc.	Vascular Solutions Inc.	\$3.0	100%					
6/18/2012	Kensey Nash Corporation	Koninklijke DSM N.V.	\$393.3	100%					
5/16/2012	Hemosphere, Inc.	CryoLife Inc.	\$21.7	100%					
Median of All	Median of All Transaction Targets \$58.6 100%								



Disclosures and Limitations: This research report is for informational and discussion purposes only. Information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the industry used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report may be used, in part, as a basis for any work that Cogent Valuation performs for you in the future at the sole discretion of Cogent Valuation. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE. This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report. Copyright © 2014 Cogent Valuation. All Rights Reserved.